Aquestive Shares Rise on Licensing Deal with Eton Pharmaceuticals
Shares of Aquestive Therapeutics rose in premarket trading after announcing an exclusive licensing agreement with Eton Pharmaceuticals for its anti-seizure medication, Libervant (diazepam) buccal film. Under the deal terms, Eton will gain exclusive rights to commercialize the product. The partnership is expected to expand access to Aquestive's treatment and provide a financial boost through licensing revenue or future royalties. The agreement highlights growing interest in innovative seizure treatments and could enhance both companies' market positions in neurological therapies. Analysts suggest that this deal may attract investor attention due to its potential for long-term value creation, especially as demand increases for non-invasive medication delivery systems.
